🇬🇧 Ransomware Protection · UK
Ransomware protection for UK hospitals and NHS trusts
The United Kingdom has faced some of the most disruptive healthcare ransomware in history — from WannaCry's crippling of the NHS in 2017 to the 2024 Synnovis attack that halted pathology across London trusts. Immune protects UK hospitals by detecting attacks in seconds, containing them before they spread, and self-healing clinical systems from immutable backups.
Immune adds the resilience layer that keeps NHS trusts and private hospitals running through an attack — including agentless coverage for the medical devices that endpoint tools can't protect.
Why ransomware resilience matters in the United Kingdom
Few health systems have learned the cost of ransomware as directly as the NHS. WannaCry in 2017 cancelled around 19,000 appointments; the 2024 Synnovis attack halted blood testing across major London trusts for months, with nearly 600 incidents and around 170 directly affecting patient care. In the UK, as everywhere, ransomware downtime is a patient-safety issue.
UK healthcare combines large, interconnected NHS trusts with private providers and a dense web of connected medical devices and third-party suppliers. That interconnection — and the reliance on shared services like pathology — is exactly what recent attacks have exploited, making containment and validated recovery essential, not optional.
Compliance & regulation
Aligned to UK healthcare requirements
Immune's controls map to the regulatory and continuity expectations placed on healthcare providers in the United Kingdom.
UK GDPR & Data Protection Act
Immune's encryption, access controls, and immutable audit logging support UK GDPR obligations around patient data and breach reporting.
NHS DSPT & Cyber Assessment
Immune's layered detection, containment, and recovery align with the security expectations placed on NHS organizations and their suppliers.
Supplier & continuity requirements
Validated, ordered recovery supports the continuity-of-care and supplier-assurance expectations exposed by recent NHS-related attacks.
Advantages
Why hospitals in the United Kingdom choose Immune
Built for NHS-scale complexity
Protects large, interconnected trusts and their shared clinical services.
Covers agentless devices
Defends the medical devices endpoint tools structurally can't reach.
Data-residency options
Deploy on-premises to keep sensitive data under UK control.
Supplier-risk aware
Network-level visibility into the third-party connections recent attacks exploited.
Continuity of care
Keeps clinical systems available through an attack.
Fast, validated recovery
Restores clinical systems in order, verified clean — not months.
Coverage
Protecting hospitals across the United Kingdom
Immune protects healthcare providers in major UK healthcare hubs including London, Manchester, Birmingham, Leeds, Glasgow, and Edinburgh — as well as regional and community hospitals nationwide.
By city
Ransomware protection by city in the United Kingdom
Explore a detailed local analysis for each city — the healthcare landscape, institutions, regulation, and how Immune protects organizations there.
Common questions
Ransomware protection in UK, answered
+Can Immune protect NHS trusts from ransomware?
Yes. Immune is designed for the large, interconnected environments NHS trusts run, delivering detection, containment, and self-healing recovery — including agentless coverage for the medical devices endpoint tools cannot protect.
+Does Immune help with UK GDPR obligations?
Immune's encryption, access controls, and immutable audit logging support UK GDPR requirements around protecting patient data and evidencing what happened during an incident.
+Can data be kept within the UK?
Yes. Immune can be deployed on-premises, keeping sensitive patient data under UK control while delivering full detection, containment, and recovery.
Explore the platform
Related capabilities
Keep your UK hospital running through ransomware
See how Immune detects, contains, and self-heals clinical systems for healthcare providers in the United Kingdom.
